PYC Therapeutics (ASX:PYC) Receives Approval to Begin Human Trials for PKD Treatment
Approval to Commence Human Trials
PYC Therapeutics (ASX: PYC) has received regulatory approval to begin human trials of its investigational drug PYC-003 for Autosomal Dominant Polycystic Kidney Disease (PKD).
Study Overview
The company will initiate a Single Ascending Dose (SAD) study, commencing with healthy volunteers (Part A) followed by PKD patients (Part B). Initial safety and efficacy data are expected in 2025.
Pre-clinical Success
PYC-003 has shown high target tissue concentration and efficacy in pre-clinical models, supporting its progression into human trials.
About PYC-003 and PKD
PKD affects approximately 1 in 1,000 people, leading to renal failure. PYC-003 targets the underlying cause of PKD, offering a potential disease-modifying treatment.
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.